Bruker AXS Wins Prestigious R&D 100 Award For Novel XFlash QUAD Detector for X-ray Microanalysis on Electron Microscopes; Bruker AXS to Demonstrate QUAD XFlash at Microscopy & Microanalysis Annual Meeting in Chicago Next Week.

MADISON, Wis. -- Bruker AXS Inc., a leading global developer and provider of life science, materials research and industrial X-ray analysis tools, announced today that R&D Magazine has selected its novel XFlash(R) QUAD detector for a 2006 R&D 100 Award. The R&D 100 awards recognize the most technologically significant products introduced into the marketplace during the past year.

The XFlash QUAD detector is a key component of Bruker AXS' recently announced QUANTAX(TM) QUAD ultra-fast and sensitive Energy-Dispersive Spectroscopy (EDS) system for X-ray microanalysis on electron microscopes. The XFlash QUAD detector is the first four channel 40 mm(2) Silicon Drift Detector (SDD) for EDS. Powered by ESPRIT(TM) software, the QUANTAX QUAD delivers significantly faster EDS results across a broad range of applications. It is especially suitable for field emission scanning electron microscopes, environmental and low vacuum scanning electron microscopes.

Roger Durst, Ph.D., Executive Vice President and Chief Technology Officer at Bruker AXS, commented: "Bruker AXS has pioneered the development of Silicon Drift Detectors technology. With their unique combination of high counting rate capability and superb energy resolution, these detectors are now widely acknowledged as the new gold standard for EDS."

Thomas Schuelein, Vice President for Microanalysis at Bruker AXS, added: "The new XFLASH QUAD complements our proven, industry-leading 10 and 30 mm(2) single-channel Xflash detectors. It is ideal for optimizing count rate at low beam current conditions and helps make new analysis techniques, like spectral imaging, even more efficient and powerful. Also, our QUANTAX EDS customers can upgrade to the XFlash QUAD in the future, should their applications require this highest level of performance."

The R&D 100 award, selected by an independent panel of judges and the editors of R&D Magazine, "provides a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year," explained the magazine's Editor-in-Chief, Tim Studt.

The 2006 award follows R&D Magazine's R&D 100 award last year to Bruker AXS for its innovative VANTEC-2000 X-ray diffraction (XRD) detector for the analysis of weakly and/or strongly scattering samples - including smallest sample traces, single crystals, epitaxial thin films, coatings, rocks, polymers, metals, steel, wood, plastics, liquids, nanomaterials and more.

Bruker AXS Microanalysis scientists will demonstrate the QUANTAX QUAD with the XFlash QUAD Detector at the Microscopy & Microanalysis 2006 Annual Meeting at the Navy Pier in Chicago July 30 through August 3, Booth 622. The affiliated Bruker Optics will exhibit at nearby Booth 604. For more information on the Microscopy & Microanalysis Annual Meeting: http://www.msa.microscopy.org/MSAMeetings/MM06/

About Bruker Biosciences (NASDAQ: BRKR)

Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biological and chemical (NBC) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-axs.com and www.bruker-biosciences.com

Cautionary Statement

Any statements contained in this press release with respect to Bruker AXS or Bruker BioSciences or their businesses that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements.